Stereotactic Body Radiation Therapy (SBRT) in Patients with Hepatocellular Cancer-a Narrative Review and Expert Opinion

Overview

Journal J Gastrointest Oncol

Date 2024 Sep 16

PMID 39279965

Authors

Sabine Gerum

Brane Grambozov

Falk Roeder

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Stereotactic body radiation therapy (SBRT) is a highly conformal technique of external beam radiotherapy precisely delivering high total (ablative) doses in a small number of fractions to clearly defined target volumes. Its development enabled efficient and safe radiation treatments in patients with localized hepatocellular cancer (HCC) unsuitable for other local treatment options. Moreover, it can be easily combined with several other therapy approaches. Thus, the aim of this narrative review is to outline the current role of SBRT in the multifocal treatment of HCC patients.

Methods: We searched PubMed for articles dealing with SBRT alone, in combination with other local or systemic treatments or in comparison to other local treatments in patients with HCC. This included original articles, reviews and conceptional articles dealing with the technique of SBRT. All articles were analysed for suitability by two independent reviewers.

Key Content And Findings: This review summarizes the currently available evidence for SBRT as a definitive treatment for HCC as well as its role within combination approaches including bridging to transplantation. SBRT is an effective and safe definitive treatment option in patients with localized HCC unsuitable for surgery and/or other local therapies based on retrospective and prospective series. Its combination with other local treatments yields superior results compared to single modality treatment based on non-randomized data. A growing number of prospective trials confirmed at least similar if not superior rates of local control with low toxicities compared to well established other local treatments even in non-selected patients.

Conclusions: SBRT is a promising tool in the treatment of HCC. It can be used either as definitive treatment, within combination approaches or as a bridging tool. Several phase III trials comparing SBRT with other local options are ongoing, which will further clarify its encouraging role.

Citing Articles

No disease left behind.

Arshad M, Lynch C, Katipally R, Pitroda S, Weichselbaum R Oncotarget. 2025; 16:163-166.

PMID: 40079896 PMC: 11906142. DOI: 10.18632/oncotarget.28700.

References

Blomgren H, Lax I, Naslund I, Svanstrom R . Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995; 34(6):861-70. DOI: 10.3109/02841869509127197. View

Matsuura M, Ishikawa A, Nakajima N, Itoh K, Matsumoto M . [Radical radiation therapy of hepatocellular carcinoma]. Nihon Igaku Hoshasen Gakkai Zasshi. 1994; 54(7):628-35. View

Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View

Cheng S, Lin Y, Chuang V, Yang P, Cheng J, Huang A . A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 1999; 14(10):1025-33. DOI: 10.1046/j.1440-1746.1999.01994.x. View

Chen A, Payao F, Chagas A, De Souza Melo Alencar R, Tani C, da Conceicao Vasconcelos K . Feasibility of SBRT for hepatocellular carcinoma in Brazil - a prospective pilot study. Rep Pract Oncol Radiother. 2021; 26(2):226-236. PMC: 8241293. DOI: 10.5603/RPOR.a2021.0035. View

Gerum S, Heinz C, Belka C, Walter F, Paprottka P, De Toni E . Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. Strahlenther Onkol. 2019; 196(4):334-348. DOI: 10.1007/s00066-019-01540-8. View

Bosse D, Ng T, Ahmad C, AlFakeeh A, Alruzug I, Biagi J . Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol. 2017; 23(6):e605-e614. PMC: 5176388. DOI: 10.3747/co.23.3394. View

Yoon S, Ryoo B, Lee S, Kim J, Shin J, An J . Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018; 4(5):661-669. PMC: 5885246. DOI: 10.1001/jamaoncol.2017.5847. View

Buckstein M, Kim E, Ozbek U, Tabrizian P, Gunasekaran G, Facciuto M . Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2022; 114(2):221-230. DOI: 10.1016/j.ijrobp.2022.05.021. View

10.

Kang J, Kim M, Cho C, Yang K, Yoo H, Kim J . Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012; 118(21):5424-31. DOI: 10.1002/cncr.27533. View

11.

Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C . The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015; 141(7):1301-9. DOI: 10.1007/s00432-015-1929-y. View

12.

Guckenberger M, Baus W, Blanck O, Combs S, Debus J, Engenhart-Cabillic R . Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol. 2020; 196(5):417-420. PMC: 7182610. DOI: 10.1007/s00066-020-01603-1. View

13.

Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D . Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017; 12(9):e0184597. PMC: 5608206. DOI: 10.1371/journal.pone.0184597. View

14.

Mendez Romero A, van der Holt B, Willemssen F, de Man R, Heijmen B, Habraken S . Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys. 2023; 117(1):45-52. DOI: 10.1016/j.ijrobp.2023.03.064. View

15.

Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M . External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021; 12(1):28-51. DOI: 10.1016/j.prro.2021.09.004. View

16.

Mourad M, Mabrut J, Chellakhi M, Lesurtel M, Prevost C, Ducerf C . Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results. Future Oncol. 2019; 15(21):2517-2530. DOI: 10.2217/fon-2019-0127. View

17.

Wahl D, Stenmark M, Tao Y, Pollom E, Caoili E, Lawrence T . Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2015; 34(5):452-9. PMC: 4872011. DOI: 10.1200/JCO.2015.61.4925. View

18.

Su T, Wu C, Liu T, Ho C, Liu C . Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. Clin Mol Hepatol. 2023; 29(2):230-241. PMC: 10121301. DOI: 10.3350/cmh.2022.0421. View

19.

Lasley F, Mannina E, Johnson C, Perkins S, Althouse S, Maluccio M . Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015; 5(5):e443-e449. DOI: 10.1016/j.prro.2015.02.007. View

20.

Mathew A, Atenafu E, Owen D, Maurino C, Brade A, Brierley J . Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer. 2020; 134:41-51. PMC: 7340168. DOI: 10.1016/j.ejca.2020.04.024. View